Other

Mowycal Lending, LLC

Endorphin, Inc.

Mowyeal Lending, LLC

Hisatek, LLC

Histatek, LLC

The Estate of Gerold K.v. Klein

Klein, Margaret L.

John C Houck

James A Clagett

Gerold K Klein

Mary MacDonald, Legal Representative

Leonard M Patt

Charles D Kimball

Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of an immune cell, a method for stabilizing the cell membrane of an immune cell, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

Small peptides and methods for blocking IGE mediated activation of an immune cell

Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucus release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

Small peptides and methods for inhibiting mucus release into airways

Methods for treating cutaneous inflammation are described. Also described is a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

Small peptides and methods for treatment of inflammation

Methods for treating cutaneous inflammation, are described. Also described is a method for inhibiting the mucous release into airways of a patient, methods for blocking IgE activation and for stabilizing the cell membrane of lymphocytes, mast cells, basophils, macrophages, monocytes, eosinophils, neutrophils, and the like, thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

Small peptides and methods for inhibiting the infiltration of eosinophils into airways

A pharmaceutical composition is described as an admixture of a pharmacological carrier and a peptide having the formula f-Met-Leu-X. X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr. Also described are methods for inhibiting the degranulation of mast cells and for treating inflammation in a patient, for example, where the inflammation is a result of a disease selected from the group consisting of asthma, rheumatoid arthritis and anaphylaxis. In addition, methods are described for inhibiting the release of cytokines in a patient, for inhibiting the release of histamines in a patient, for inhibiting the release leukotrienes in a patient, for reducing adhesion, migration and aggregation of lymphocytes, eosinophils and neutrophils to a site of inflammation in a patient, for reducing the production of IgE antibodies at site of inflammation in a patient, and for inhibiting increased vascular permeability at site of inflammation in a patient. The methods use the described pharmaceutical composition.

Small peptides and methods for treatment of asthma and inflammation

Methods for treating allergies, cutaneous inflammation, arthritis, chronic obstruction pulmonary disease and treating chronic inflammatory bowel disease are described. Also described is a method for inhibiting the infiltration of eosinophils into airways of a patient, a method for inhibiting the mucous release into airways of a patient, a method for blocking IgE activation of a lymphocyte, a method for stabilizing the cell membrane of a lymphocyte; thereby preventing their further involvement in the increased inflammatory response to an IgE antigen challenge, and a method for inhibiting the migration of T-cells. Such methods involve administering to said patient a therapeutically effective amount of a peptide having the formula f-Met-Leu-X, wherein X is selected from the group consisting of Tyr, Tyr-Phe, Phe-Phe and Phe-Tyr.

Method for treatment of allergic reaction using formyl peptide

Method is described for obtaining a novel proteolytic mixture containing escharase from bromelain.

Proteolytic mixture containing escharase and method of isolating same

Immunostimulatory peptide is isolated from bovine thymus tissue and is useful to treat mammals and birds at risk from viral or fungal infections or other trauma.

Immune stimulation

An endorphin peptide is described that has a molecular weight by amino acid analysis of about 14,000 daltons, an infrared spectrum substantially as shown in FIG. 5, and an amino acid analysis substantially as follows:

Endorphins having placental or pancreatic origin

Disclosure relates to novel escharase containing proteolytic enzyme mixture derived from bromelain useful for the digestion, dissection and separation of non-viable, devitalized tissue, especially eschar tissue from viable tissue in a host organ.

Enzyme mixture

Disclosure relates to novel hydrolytic enzyme product derived from the pineapple plant useful for the digestion, dissection and separation of non-viable, devitalized tissue, especially eschar tissue from viable tissue in a mammalian host.

Growing community of inventors

Seattle, WA, United States of America

John C Houck